Adage Capital Partners GP L.L.C. Has $33.93 Million Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Adage Capital Partners GP L.L.C. boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 97.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 490,313 shares of the company's stock after purchasing an additional 241,556 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.39% of Henry Schein worth $33,930,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Versant Capital Management Inc lifted its position in Henry Schein by 274.6% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $32,000 after acquiring an additional 335 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Henry Schein by 3,347.1% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company's stock valued at $41,000 after purchasing an additional 569 shares during the period. Quent Capital LLC grew its holdings in Henry Schein by 91.2% during the 4th quarter. Quent Capital LLC now owns 677 shares of the company's stock valued at $47,000 after purchasing an additional 323 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after buying an additional 143 shares in the last quarter. Finally, City State Bank acquired a new stake in shares of Henry Schein during the fourth quarter valued at about $55,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Trading Down 2.0 %

Shares of HSIC stock traded down $1.30 on Wednesday, reaching $64.86. 232,891 shares of the stock were exchanged, compared to its average volume of 1,616,073. The stock has a market cap of $7.95 billion, a PE ratio of 26.69, a P/E/G ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The stock has a 50 day moving average price of $68.73 and a 200 day moving average price of $71.72.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the company earned $0.66 earnings per share. The firm's quarterly revenue was up 5.8% on a year-over-year basis. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now directly owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. The trade was a 9.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Analyst Ratings Changes

HSIC has been the subject of several recent analyst reports. StockNews.com cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Wells Fargo & Company assumed coverage on shares of Henry Schein in a research report on Friday, February 14th. They issued an "equal weight" rating and a $80.00 price target for the company. UBS Group cut their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Bank of America upgraded Henry Schein from an "underperform" rating to a "buy" rating and lifted their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. Finally, Barrington Research restated an "outperform" rating and set a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.